ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: 2561

Patient-Centricity: The Keystone to Recruitment and Retention of Research Participants for the Lupus Landmark Study and the Success of the Lupus Nexus

(2547–2566) ARP Posters I

10:30AM-12:30PM: Abstract Number: 2508

Patient-Reported Outcomes in ANCA-Associated Vasculitis: Early Findings from a Prospective Real-World Cohort

(2504–2523) Vasculitis – ANCA-Associated Poster III

10:30AM-12:30PM: Abstract Number: 2539

Patient-reported outcomes in patients with polymyalgia rheumatica under rheumatology care: baseline data from the ENRICH-PMR cohort

(2524–2546) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

10:30AM-12:30PM: Abstract Number: 2384

Patient-Reported Quality of Life in SLE: Association with Biomarker-Derived Disease Activity Index (L-DAI) and hSLEDAI in a Prospective Cohort

(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2290

Patterns and Predictors of Clinical Improvement in Patients with Sjögren’s Disease: A Longitudinal Analysis of ESSDAI and ESSPRI Improvements

(2290–2304) Sjögren’s Disease – Basic & Clinical Science Poster III: Treatment and Trial Outcome Measures

10:30AM-12:30PM: Abstract Number: 2067

Patterns of Comorbidity in Idiopathic Inflammatory Myopathies: A Cross-sectional Analysis of Disease Burden and Risk Factors

(2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 2533

Patterns of skin lesion transcriptomics in different forms of vasculitis

(2524–2546) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

10:30AM-12:30PM: Abstract Number: 2103

PCRX-201 High-Capacity Adenovirus Serotype 5 Gene Therapy Demonstrates Sustained Clinical Efficacy and Safety in Patients With Knee Osteoarthritis

(2079–2105) Osteoarthritis – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 2549

Perceived Dignity in Patients With Rheumatic Disease

(2547–2566) ARP Posters I

10:30AM-12:30PM: Abstract Number: 2161

Perceptions of the Importance of Pediatric Rheumatology Education in Pediatric Residency: A Needs Assessment

(2159–2194) Professional Education Poster

10:30AM-12:30PM: Abstract Number: 1914

Performance Comparison of Artificial Intelligence tools ChatGPT, Bing AI, and Google Bard for Clinical Rheumatology Decision Support: When AI Talks Rheumatology

(1914–1935) Health Services Research Poster III

10:30AM-12:30PM: Abstract Number: 1964

Performance of Artificial Intelligence-Based Salivary Gland Ultrasound in Sjögren Syndrome

(1936–1971) Imaging of Rheumatic Diseases Poster

10:30AM-12:30PM: Abstract Number: 1950

Pericoronary fat enhancement in rheumatoid arthritis differs from controls and associates with coronary atherosclerosis independently of epicardial fat volume

(1936–1971) Imaging of Rheumatic Diseases Poster

10:30AM-12:30PM: Abstract Number: 2307

Peripheral Manifestations In Axial And Peripheral Spondyloarthritis: A Systematic Literature Review On Their Assessment In Clinical Trials

(2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2327

Persistent Pain in PsA: A Distinct Phenotype of Depression, Fatigue, And Catastrophizing

(2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].